A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients
This Phase I interventional study (n=64) assesses feasibility of a resilience-focused 10-week community of practice programme incorporating one group-administered psilocybin-assisted therapy session for patients with end-of-life distress.
Details
Single-group, early-phase study delivering a 10‑week research-informed community of practice (weekly 2‑hour sessions) with one mid-programme group psilocybin-assisted therapy session for patients with a terminal diagnosis and end-of-life distress.
Data collection focuses on feasibility and safety (biomedical measures during dosing, adverse events) and mental health impacts using quantitative questionnaires at baseline, during, immediately post-programme and at six months, plus qualitative surveys and exit interviews. Research data coordinated via REDCap hosted by Island Health.